The Effect of DA9301 on Tablet Computer-Induced Asthenopia

Clinical Trial to Investigate the Effect of DA9301 on Tablet Computer-induced Asthenopia in Humans

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02641470

Enrollment

Registered

2015-12-29

Start date

2014-01-31

Completion date

Unknown

Last updated

2015-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthenopia

Brief summary

Asthenopia or eye strain describes nonspecific symptoms of an eye when it is tired from intensive work. Vaccinium uliginosum is a flowering plant in the genus Vaccinium. This plant is native to cool temperature regions of the Northern Hemisphere. Considering its antioxidative ingredients, the extract of Vaccinium uliginosum is expected to play a significant role in treating various ocular pathologies. The investigators performed a randomized, case-controlled study in healthy subjects and investigated the protective effect of Vaccinium uliginosum extract (DA-9301) on tablet computer-induced asthenopia.

Interventions

DIETARY_SUPPLEMENTDA9301 (Vaccinium uliginosum extract)

DIETARY_SUPPLEMENTPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1\. Healthy subject aged 20 to 65 years with more than 2 hours of daily use of a smart phone or computer including a tablet and television

Exclusion criteria

1. Ocular disease in either eye * Ocular surface disease * Best corrected visual acuity \< 20/30 * Intraocular pressure \> 21 mmHg * Optical coherence tomography proven retinal nerve fiber defect * Significant cataract (lens opacities classification system III) * Significant entropion or ectropion * Significant tear drainage problem proved with fluorescein dye dilution test 2. Soft or Hard contact lens use 3 or more days a week 3. History of oral intake of health supplement designed to improve asthenopia within 4 weeks before participating this study 4. Pregnant woman 5. Systemic disease * Uncontrolled hypertension (systolic /diastolic blood pressure \> 140/90mmHg) * Uncontrolled diabetes mellitus (fasting blood glucose level \> 180mg/dL) * Rheumatoid arthritis * Malignant disease * Active hepatitis (type B and C) * Acute or chronic infectious disease * Renal disease

Design outcomes

Primary

Measure	Time frame
Change of the modified questionnaire scores proposed by Ames et al.	before and immediately after tablet computer use on Day 0 and Day 29 (deviation window: Day 21-31)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026